Streetbeat News

Stock Prices

ENVB

Enveric Biosciences has reported results from animal studies showing oral bioavailability and a well-tolerated side effect profile for EB-373. The results could potentially lead to further development and testing of the drug.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:04 pm

CYRX

Over the past 3 months, 8 analysts have published their opinion on CryoPort (NASDAQ:CYRX) stock. The company has an average price target of $25.12, a decrease of 20.25% from the previous average price target of $31.50. The majority of the ratings are bullish.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 12:01 pm

BFAM

Bright Horizons Family (NYSE:BFAM) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 indifferent, 1 somewhat bearish, and 1 bearish. The average 12-month price target for the company, according to 5 analysts, is $87.4, which has increased by 9.7% over the past month.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 12:01 pm

PINS

Over the past 3 months, 11 analysts have published their opinion on Pinterest (NYSE:PINS) stock. The average price target is $27.45, which is lower than the current price of $28.71. The majority of the analysts are indifferent about the stock, with only 1 bullish and 2 somewhat bullish ratings.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 12:00 pm

KBR

In the last quarter, KBR (NYSE:KBR) received six analyst ratings, three bullish, three somewhat bullish, and none bearish or indifferent. The average price target is $72.17, indicating an upside from the current price of $64.18. The average price target has increased by 8.53% over the past month.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 12:00 pm

BRY

Analysts have provided ratings for Berry Corp (NASDAQ:BRY) in the last quarter, with an average price target of $9.6, implying an upside from the current price of $7.23. The current average has decreased by 12.73% from the previous average price target of $11.00.

Portfolio Pulse from Benzinga Insights

July 17, 2023 | 12:00 pm

GMVHF

GMVHY

MGM

Entain PLC plans to acquire Angstrom Sports for a total consideration of £81 million plus contingent payments totaling a maximum of £122 million, payable over three years. The acquisition is expected to boost Entain's position in the U.S. sports betting market by enhancing its analytics, risk, and pricing capabilities. The deal is expected to close in Q3 2023. BetMGM, a joint venture owned by Entain and MGM Resorts International, will benefit from the acquisition.

Portfolio Pulse from Lekha Gupta

July 17, 2023 | 12:00 pm

INTC

NVDA

QCOM

TSM

CEOs of Intel Corp and Qualcomm Inc are set to visit Washington to discuss China policy, including market conditions, export controls, and other matters affecting their businesses. U.S. officials are considering strengthening export rules affecting high-performance computing chips and shipments to Huawei Technologies Co Ltd, which could impact Intel and Qualcomm. The potential rule tightening could also significantly affect Nvidia Corp. The executives aim to explain to government officials the repercussions of further stricter embargo on the Chinese semiconductor industry.

Portfolio Pulse from Anusuya Lahiri

July 17, 2023 | 11:59 am

MIRM

Trading of Mirum Pharmaceuticals' shares has been temporarily halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:56 am

PRDS

MediPacific has agreed to acquire Pardes Biosciences for $2.02-$2.19 per share in cash plus contingent value rights. This has led to a rise in Pardes Biosciences' share price.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:54 am